CN107417603B - 一种克里唑替尼中间体制备方法 - Google Patents
一种克里唑替尼中间体制备方法 Download PDFInfo
- Publication number
- CN107417603B CN107417603B CN201710348511.6A CN201710348511A CN107417603B CN 107417603 B CN107417603 B CN 107417603B CN 201710348511 A CN201710348511 A CN 201710348511A CN 107417603 B CN107417603 B CN 107417603B
- Authority
- CN
- China
- Prior art keywords
- fluorophenyl
- dichloro
- ethoxy
- compound
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 title claims abstract description 33
- 239000002146 L01XE16 - Crizotinib Substances 0.000 title claims abstract description 32
- 229960005061 crizotinib Drugs 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 59
- 238000006243 chemical reaction Methods 0.000 claims abstract description 43
- IEKMAKBQCRKWLS-SSDOTTSWSA-N 3-[(1r)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-2-amine Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C1=CC=CN=C1N IEKMAKBQCRKWLS-SSDOTTSWSA-N 0.000 claims abstract description 24
- VGDOUCIQKWTGJY-SSDOTTSWSA-N 3-[(1r)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-2-nitropyridine Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C1=CC=CN=C1[N+]([O-])=O VGDOUCIQKWTGJY-SSDOTTSWSA-N 0.000 claims abstract description 19
- HDMGAZBPFLDBCX-UHFFFAOYSA-M potassium;sulfooxy sulfate Chemical compound [K+].OS(=O)(=O)OOS([O-])(=O)=O HDMGAZBPFLDBCX-UHFFFAOYSA-M 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 15
- 238000005893 bromination reaction Methods 0.000 claims abstract description 10
- 238000011946 reduction process Methods 0.000 claims abstract description 9
- 230000008569 process Effects 0.000 claims abstract description 8
- 150000003842 bromide salts Chemical class 0.000 claims abstract description 6
- 238000006722 reduction reaction Methods 0.000 claims abstract description 6
- 238000001308 synthesis method Methods 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 49
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 39
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 33
- 238000001914 filtration Methods 0.000 claims description 26
- 238000003756 stirring Methods 0.000 claims description 24
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 claims description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 239000007864 aqueous solution Substances 0.000 claims description 14
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 10
- 239000012043 crude product Substances 0.000 claims description 8
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 claims description 8
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 6
- 230000002194 synthesizing effect Effects 0.000 claims description 6
- 239000003513 alkali Substances 0.000 claims description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 5
- 235000011181 potassium carbonates Nutrition 0.000 claims description 5
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 claims description 4
- 229910001623 magnesium bromide Inorganic materials 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 229940125904 compound 1 Drugs 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- URFUZAZEKBBCEY-ZCFIWIBFSA-N 5-bromo-3-[(1r)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-2-amine Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C1=CC(Br)=CN=C1N URFUZAZEKBBCEY-ZCFIWIBFSA-N 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 239000011736 potassium bicarbonate Substances 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 2
- 235000011118 potassium hydroxide Nutrition 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 2
- 229910004878 Na2S2O4 Inorganic materials 0.000 claims 2
- CSMWJXBSXGUPGY-UHFFFAOYSA-L sodium dithionate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)S([O-])(=O)=O CSMWJXBSXGUPGY-UHFFFAOYSA-L 0.000 abstract description 13
- 229940075931 sodium dithionate Drugs 0.000 abstract description 13
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 3
- 239000003960 organic solvent Substances 0.000 abstract description 3
- 238000009903 catalytic hydrogenation reaction Methods 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 27
- 239000000203 mixture Substances 0.000 description 23
- 239000000543 intermediate Substances 0.000 description 20
- 239000011541 reaction mixture Substances 0.000 description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 16
- 239000003054 catalyst Substances 0.000 description 14
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 12
- -1 2, 6-dichloro-3-fluorophenyl Chemical group 0.000 description 10
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 10
- 229910001220 stainless steel Inorganic materials 0.000 description 10
- 239000010935 stainless steel Substances 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 229910052763 palladium Inorganic materials 0.000 description 8
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 7
- 229910052593 corundum Inorganic materials 0.000 description 7
- 229910001845 yogo sapphire Inorganic materials 0.000 description 7
- HLTDBMHJSBSAOM-UHFFFAOYSA-N 2-nitropyridine Chemical compound [O-][N+](=O)C1=CC=CC=N1 HLTDBMHJSBSAOM-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000002808 molecular sieve Substances 0.000 description 5
- 229910052697 platinum Inorganic materials 0.000 description 5
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 4
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 238000010268 HPLC based assay Methods 0.000 description 3
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 238000003912 environmental pollution Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 description 1
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 229910001503 inorganic bromide Inorganic materials 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011112 process operation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pyridine Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710348511.6A CN107417603B (zh) | 2017-05-17 | 2017-05-17 | 一种克里唑替尼中间体制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710348511.6A CN107417603B (zh) | 2017-05-17 | 2017-05-17 | 一种克里唑替尼中间体制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107417603A CN107417603A (zh) | 2017-12-01 |
CN107417603B true CN107417603B (zh) | 2020-08-11 |
Family
ID=60424726
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710348511.6A Active CN107417603B (zh) | 2017-05-17 | 2017-05-17 | 一种克里唑替尼中间体制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107417603B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108640870A (zh) * | 2018-04-12 | 2018-10-12 | 常州大学 | 一种合成6-溴甲基-3-甲氧基-2-硝基吡啶的方法 |
CN112225722A (zh) * | 2020-11-12 | 2021-01-15 | 张家港威胜生物医药有限公司 | 利用微通道反应器制备克唑替尼中间体的方法 |
CN113651787B (zh) * | 2021-07-28 | 2023-11-03 | 浙江工业大学 | 一种吡喃-2-酮类化合物的无溶剂球磨-氨基酸耦合合成法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102898361A (zh) * | 2012-10-08 | 2013-01-30 | 鲁东大学 | 一种制备2-氯-3-氨基-4-甲基吡啶的方法 |
WO2014068587A2 (en) * | 2012-10-29 | 2014-05-08 | Biophore India Pharmaceuticals Pvt. Ltd. | An improved process for the synthesis of dabigatran and its intermediates |
CN105820113A (zh) * | 2015-01-07 | 2016-08-03 | 爱技特科技(北京)有限公司 | 一种克唑替尼手性中间体的制备方法 |
CN105924431A (zh) * | 2016-05-31 | 2016-09-07 | 甘肃皓骏医药科技有限责任公司 | 化合物克唑替尼的合成工艺 |
CN107365301A (zh) * | 2016-05-12 | 2017-11-21 | 上海裕兰生物科技有限公司 | 一种克唑替尼的合成方法及其中间体制备方法 |
-
2017
- 2017-05-17 CN CN201710348511.6A patent/CN107417603B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102898361A (zh) * | 2012-10-08 | 2013-01-30 | 鲁东大学 | 一种制备2-氯-3-氨基-4-甲基吡啶的方法 |
WO2014068587A2 (en) * | 2012-10-29 | 2014-05-08 | Biophore India Pharmaceuticals Pvt. Ltd. | An improved process for the synthesis of dabigatran and its intermediates |
CN105820113A (zh) * | 2015-01-07 | 2016-08-03 | 爱技特科技(北京)有限公司 | 一种克唑替尼手性中间体的制备方法 |
CN107365301A (zh) * | 2016-05-12 | 2017-11-21 | 上海裕兰生物科技有限公司 | 一种克唑替尼的合成方法及其中间体制备方法 |
CN105924431A (zh) * | 2016-05-31 | 2016-09-07 | 甘肃皓骏医药科技有限责任公司 | 化合物克唑替尼的合成工艺 |
Non-Patent Citations (1)
Title |
---|
A facile, regioselective and controllable bromination of aromatic amines using a CuBr2/Oxone1 system3;Xin-Le Li,等;《RSC Adv.》;20130530;第3卷;第12091-12095页 * |
Also Published As
Publication number | Publication date |
---|---|
CN107417603A (zh) | 2017-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107417603B (zh) | 一种克里唑替尼中间体制备方法 | |
Cheng et al. | Palladium catalyzed acetoxylation of benzylic C–H bonds using a bidentate picolinamide directing group | |
CN105777710B (zh) | 一种艾乐替尼的合成方法 | |
CN102079737B (zh) | 一种制备芹菜素的方法 | |
CN103570633B (zh) | 吉非替尼的制备方法 | |
CN111349049B (zh) | 一种法匹拉韦及其中间体的合成工艺 | |
CN114044777B (zh) | 一种磷酸芦可替尼的制备方法 | |
CN104447934A (zh) | 一种醋酸阿比特龙的纯化方法 | |
CN102977017B (zh) | 一种由铜化合物催化制备6(5h)-菲啶酮的方法 | |
CN106187901B (zh) | 一种右美托咪定及其中间体的制备方法 | |
CN109608468B (zh) | 一种枸橼酸托法替布杂质及其合成方法和用途 | |
CN103193763B (zh) | 一种来那度胺的制备方法 | |
CN106397227B (zh) | 一种达泊西汀盐酸盐的制备方法 | |
CN103896858B (zh) | 胞嘧啶的制备工艺 | |
CN106632424A (zh) | 以1‑(2‑吡啶)‑9‑苄基‑β‑咔啉为配体的氯化铜配合物及其合成方法和应用 | |
CN110117255A (zh) | 一种乐伐替尼杂质及其制备方法 | |
CN104003943A (zh) | 一种替格瑞洛中间体的制备方法 | |
CN105669686B (zh) | 一种6-(叔丁氧羰基)八氢呋喃[2,3-c]吡啶-4-羧酸的合成方法 | |
CN104086488A (zh) | 一种2,4,6-三取代嘧啶类化合物的合成方法 | |
CN109879800B (zh) | 一种贝他斯汀药物中间体的制备工艺 | |
CN103351291A (zh) | 一种天然根皮苷半合成制备根皮素工艺 | |
CN107641101B (zh) | 一种菲啶酮类化合物的制备方法 | |
CN104177293A (zh) | 5-氨基-7-三氟甲基喹啉及5-三氟甲基-7-氨基喹啉的合成方法 | |
CN104387385B (zh) | 6-羧酸甲酯-2-氧-7-氮杂吲哚及其制备方法与应用 | |
CN110105371B (zh) | 一种多拉达唑原料药中的杂质及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20181217 Address after: 215634 No. 2 Nanjing Middle Road, Yangtze River Chemical Industrial Park, Zhangjiagang Free Trade Zone, Suzhou City, Jiangsu Province Applicant after: ZHANG JIA GANG VINSCE BIO-PHARM Co.,Ltd. Address before: 215634 Building D, No. 7 Guangdong Road, Zhangjiagang Free Trade Zone, Suzhou City, Jiangsu Province, 3rd Floor Applicant before: JIANGSU SWELLXIN BIO-PHARM. Pty Ltd. Applicant before: ZHANG JIA GANG VINSCE BIO-PHARM Co.,Ltd. Applicant before: WUYANG WEISEN BIOMEDICAL CO.,LTD. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A preparation method of crizotinib intermediate Effective date of registration: 20210930 Granted publication date: 20200811 Pledgee: Agricultural Bank of China Limited Zhangjiagang branch Pledgor: ZHANG JIA GANG VINSCE BIO-PHARM Co.,Ltd. Registration number: Y2021320010400 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 215634 No. 2 Nanjing Middle Road, Yangtze River Chemical Industrial Park, Zhangjiagang Free Trade Zone, Suzhou City, Jiangsu Province Patentee after: Weisheng Biomedical (Suzhou) Co.,Ltd. Address before: 215634 No. 2 Nanjing Middle Road, Yangtze River Chemical Industrial Park, Zhangjiagang Free Trade Zone, Suzhou City, Jiangsu Province Patentee before: ZHANG JIA GANG VINSCE BIO-PHARM Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: No. 2, Nanjing Middle Road, Jiangsu Yangzijiang Chemical Industrial Park, Zhangjiagang Free Trade Zone, Suzhou City, Jiangsu Province, 215634 Patentee after: Wison Biomedical (Suzhou) Co.,Ltd. Address before: 215634 No. 2 Nanjing Middle Road, Yangtze River Chemical Industrial Park, Zhangjiagang Free Trade Zone, Suzhou City, Jiangsu Province Patentee before: Weisheng Biomedical (Suzhou) Co.,Ltd. |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20221031 Granted publication date: 20200811 Pledgee: Agricultural Bank of China Limited Zhangjiagang branch Pledgor: ZHANG JIA GANG VINSCE BIO-PHARM Co.,Ltd. Registration number: Y2021320010400 |